Welcome to our book review site go-pdf.online!
You may have to Search all our reviewed books and magazines, click the sign up button below to create a free account.
Applications of Viruses for Cancer Therapy
Advances in Cancer Research provides invaluable information on the exciting and fast-moving field of cancer research. This thematic volume looks at "Applications of viruses for cancer therapy". With outstanding and original reviews, this volume covers topics such as Cancer Terminator Viruses and Approaches for Enhancing Therapeutic Outcomes, esign of improved oncolytic adenoviruses, and Adenovirus-based immunotherapies for cancer. - Provides invaluable information on the exciting and fast-moving field of cancer research - This thematic volume looks at "Applications of viruses for cancer therapy" - Outstanding and original reviews
Bio-Nanomedicine for Cancer Therapy
The book covers the latest developments in biologically-inspired and derived nanomedicine for cancer therapy. The purpose of the book is to illustrate the significance of naturally-mimicking systems for enhancing the dose delivered to the tumor, to improve stability, and prolong the circulation time. Moreover, readers are presented with advanced materials such as adjuvants for immunostimulation in cancer vaccines. The book also provides a comprehensive overview of the current status of academic research. This is an ideal book for students, researchers, and professors working in nanotechnology, cancer, targeted drug delivery, controlled drug release, materials science, and biomaterials as well as companies developing cancer immunotherapy.
Vector-based Cancer Immunotherapy
Immunotherapy is a clinically proven concept to prevent and treat diverse diseases. Therapeutic monoclonal antibodies (mAb) have transformed cancer patient survival and the quality of life for patients with inflammatory and autoimmune diseases. Vaccination with attenuated viruses or microbial virulence factors is a validated strategy to control infectious disease and has eradicated the global pandemic Smallpox infection. Recently, the concept of encoding transgenes, such as the receptor-binding COVID-19 spike protein, cytokines, antibodies, or immunogenic tumor antigens into non-viral or viral vectors has been validated as a powerful means to achieve vaccination for protection against pandemic infections, and cancer immunotherapy respectively. For certain immunotherapeutic targets and mechanisms, vector-based targeting offers distinct advantages over the traditional protein format. For example, in cancer immunotherapy vectorization may enable local delivery, production, and tumor-enriched exposure of powerful immune-modulatory antibodies, for example anti-CTLA-4 or anti-CD28 that are too toxic to allow full therapeutic dosing upon systemic administration.
Cancer-Causing Viruses and Their Inhibitors
Cancer-causing viruses, also called oncoviruses, play a key role in the development of certain cancers. They contribute to genetic changes that disrupt the cell cycle machinery, interfering with functions such as cell growth. Cancer-Causing Viruses and Their Inhibitors presents a plethora of research from internationally reputed contributors who di
Combinational Immunotherapy of Cancer: Novel Targets, Mechanisms, and Strategies
Cancer immunotherapy, including immune checkpoint inhibitors (ICIs) and chimeric antigen receptor T-cell (CAR-T) therapy, has revolutionized the paradigm in cancer treatment. However, the clinical outcome of immunotherapy varies considerably among patients and only a minority of patients achieve long-term clinical benefits. This is largely attributed to the fact that existing cancer immunotherapies, which concentrate on several classical targets (CTAL-4, PD-1/PD-L1, etc.) and limited types of immune cell populations (T cells), are insufficient to cope with the complexity of highly heterogeneous tumor microenvironment (TME). This calls for more efforts to not only expand our toolbox for manip...
Nanoparticle-Mediated Signaling Rewiring and Reprogramming of Immune Responses
Dr. Quintana is the founder of AnTolRx. The other Topic Editor declares no competing interests.
